Sacubitril: all 46 studies that test it
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyRecruitingNCT07491718Not applicable
- Sacubitril/Allisartan for Hypertensive Patients With Overweight or ObesityNot yet recruitingNCT07241338Phase 4
- Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection FractionRecruitingNCT07192341Not applicable
- Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery DiseaseRecruitingNCT06917664Phase 4
- Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection FractionNot yet recruitingNCT06712030Phase 3
- Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural TanzaniaRecruitingNCT06704633Phase 4
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic NephropathyNot yet recruitingNCT06501651Phase 4
- Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsRecruitingNCT06218199Phase 4
- Determination of Drug Levels for Pharmacotherapy of Heart FailureNot yet recruitingNCT06035978Phase 4
- The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection FractionRecruitingNCT05508035Phase 3
- Enhancing the Natriuretic Peptide System in HFpEFEnrolling by invitationNCT05279742Phase 1/2
- A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 StudyCompletedNCT06149104Phase 3Results posted
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCCCompletedNCT04023227Phase 4Results posted
- Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)CompletedNCT03988634Phase 3Results posted
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HFCompletedNCT03785405Phase 3Results posted
- The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MICompletedNCT03552575Phase 3Results posted
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsCompletedNCT03066804Phase 3Results posted
- An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionCompletedNCT01281306Phase 2Results posted
- Efficacy and Safety of LCZ696A in Patients With Essential HypertensionCompletedNCT00549770Phase 2Results posted
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/AllisartanCompletedNCT07704697Phase 3
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With AmlodipineCompletedNCT07704684Phase 3
- The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEFCompletedNCT07417215Phase 4
- Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart FailureCompletedNCT07023016Phase 2/3
- Sacubitril/Valsartan Versus Valsartan in Heart FailureCompletedNCT05881720Phase 4
- Effects and Safety of Sacubitril/Valsartan on Refractory HypertensionStatus unknownNCT05545059Phase 3
- Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection FractionCompletedNCT05387967Phase 4
- Lifestyle and Pharmacological Interventions in Hypertrophic CardiomyopathyCompletedNCT05366101Phase 2/3
- Sacubitril/Valsartan for CKD5 Stage Dialysis PatientsCompletedNCT05243199Phase 4
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart FailureTerminatedNCT05117736Not applicable
- The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEFStatus unknownNCT05089539Phase 2
- Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.Status unknownNCT04929600Phase 4
- Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With HypertensionStatus unknownNCT04800081Not applicable
- Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)WithdrawnNCT04637555Phase 3
- Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory StudyCompletedNCT04587947Not applicable
- The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF ValueStatus unknownNCT04572724Phase 4
- Early Treatment of ARNI on Myocardial Remodeling and ProgressStatus unknownNCT04342351Phase 4
- Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTDStatus unknownNCT04197050Phase 4
- Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart FailureStatus unknownNCT04107220Not applicable
- Sacubitril/Valsartan vs Lifestyle in Hypertrophic CardiomyopathyCompletedNCT03832660Phase 2
- Prevention of Cardiac Dysfunction During Breast Cancer TherapyCompletedNCT03760588Phase 2
- Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and NeprilysinStatus unknownNCT03553303Phase 4
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin InhibitionWithdrawnNCT03508739Phase 3
- Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart FailureWithdrawnNCT03415906Phase 2
- Comparing ARNI With ACE Inhibitor on Endothelial FunctionWithdrawnNCT03119623Phase 4
- Strategies to Promote Cessation in Smokers Who Are Not Ready To QuitCompletedNCT02905656Not applicable
- Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart FailureTerminatedNCT02787798Phase 4